Form 4: Revance Therapeutics CFO Tobin Schilke Acquires 1,000 Shares Through Employee Stock Purchase Plan

Revance Therapeutics' CFO, Tobin Schilke, acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan at a price of $2.1845 per share.

Summary

• On June 30, 2024, Tobin Schilke, CFO of Revance Therapeutics, Inc., acquired 1,000 shares of common stock.
• The acquisition was made through the company's 2014 Employee Stock Purchase Plan.
• The price per share was $2.1845.
• Following the transaction, Mr. Schilke directly owns 193,666 shares of Revance Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. The CFO's participation in the employee stock purchase plan could be seen as a slightly positive signal, but it's not a major event.

Positives

• The CFO's participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, but it provides transparency into insider trading activities.

Key Dates

Keywords

Revance Therapeutics, RVNC, Tobin Schilke, CFO, Employee Stock Purchase Plan, Stock Acquisition, Form 4